BPC-157 vs TB-500.
Both are the canonical underground healing peptides. They overlap mechanistically but aren't redundant — and most experienced users run them together. Here's how to think about each one separately.
Same family, same fundamentals.
Both are underground recovery staples. Both accelerate soft-tissue healing in animal models with consistent, large effect sizes. Both have thin human clinical data — almost everything we know about real-world dosing comes from self-experimenters reporting outcomes online.
Both inject subcutaneously into abdominal fat as the default route. Both reconstitute identically: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL working solution. Both keep for 4–6 weeks refrigerated.
The differences that actually matter.
BPC-157 acts through angiogenesis — promoting new blood vessel formation at injury sites — and through nitric oxide pathway modulation. The animal data is heaviest on tendons, ligaments, and the GI tract. Real-world reports also include gut healing, mood improvement, and joint pain reduction — effects beyond simple tissue repair.
TB-500 acts by sequestering actin, which lets cells migrate more freely to sites of injury. It drives systemic regeneration: the same dose injected into your abdomen reaches every tissue type in the body. Real-world reports focus on muscle, tendon, and full-body recovery from training.
The dosing cadence differs because the mechanisms differ. BPC-157 is daily because the angiogenesis pathway responds to sustained signal. TB-500 is 2–3×/week because the actin-sequestration effect persists at the tissue level for days after a single dose.
Which one fits your goal.
For a localized soft-tissue issue — a tendon that won't heal, a stubborn shoulder, gut inflammation — BPC-157 alone is a reasonable first try. The mechanism is right for the problem.
For systemic recovery — overtrained, post-surgery, multiple aging joints — TB-500 alone is the better solo pick. It distributes everywhere and lets the body prioritize wherever needs the most repair.
For most people, the answer is both. They have complementary mechanisms and the trial-tested pairing produces faster results than either alone. The canonical protocol: daily BPC-157 at 250–500 mcg + 2× weekly TB-500 at 2.5 mg for a 4–6 week loading cycle, then maintenance on BPC-157 only.
Reconstitute either one in seconds.
Common questions.
Can I stack BPC-157 and TB-500 in the same syringe?+
Yes — they're stable together in solution for the duration of an injection. Many vendors sell pre-blended vials. If you want flexibility to dose them on different schedules, reconstitute separately and just inject back-to-back from two syringes.
Which works faster — BPC-157 or TB-500?+
BPC-157 typically shows effects in 1–2 weeks at proper doses. TB-500 takes 3–4 weeks of a loading cycle to feel meaningfully different. If you want fast feedback on whether peptide therapy works for your issue, BPC-157 is the faster signal.
Are there cancer risks with either?+
Both can theoretically accelerate growth of existing tumors via the same angiogenesis and tissue-regeneration pathways that make them work. Neither causes cancer. If you have any cancer history, this is a real concern, not a fig leaf — talk to your oncologist.